Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Quisinostat (JNJ-26481585) 是一种高效的,具有口服活性的 pan-HDAC 抑制剂,对 HDAC1、HDAC2、HDAC4、HDAC10、HDAC11 作用的 IC50值范围为 0.11-0.64 nM。它在成神经细胞瘤中能诱导自噬,具有广泛的抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 343 | 现货 | ||
2 mg | ¥ 497 | 现货 | ||
5 mg | ¥ 997 | 现货 | ||
10 mg | ¥ 1,490 | 现货 | ||
25 mg | ¥ 2,480 | 现货 | ||
50 mg | ¥ 3,570 | 待询 | ||
100 mg | ¥ 5,390 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,090 | 现货 |
产品描述 | Quisinostat (JNJ-26481585) (JNJ-26481585) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. |
靶点活性 | HDAC1:0.11 nM |
体外活性 | Quisinostat exerts broad-spectrum antiproliferative activity against a wide panel of cancer cell lines including lung, colon, breast, prostate, and ovarian cell lines at nanomolar concentrations. JNJ-26481585 shows activity toward all HDAC enzymes tested with highest potency in vitro observed toward recombinant HDAC1 (IC50, 0.11±0.03 nM), which is comparable with the potency observed toward HDAC1-immunoprecipitated complexes from tumor cells (IC50, 0.16±0.02 nM). Lowest in vitro potency is observed toward HDAC6, 7 and 9 (IC50, 32.1-119 nM) [1]. |
体内活性 | JNJ-26481585 induces continuous H3 acetylation in tumor tissue in vivo. JNJ-26481585, a "second-generation" HDAC inhibitor with prolonged pharmacodynamic response in vivo. In agreement with the hypothesis, JNJ-26481585 showed superior efficacy compared with both standard of care agents and first-generation HDAC inhibitors in preClinicalal tumor models. These studies suggest that an HDAC inhibitor with continuous pharmacodynamic activity may show activity in solid tumor malignancies[1]. |
别名 | 奎诺司他, JNJ-26481585 |
分子量 | 394.47 |
分子式 | C21H26N6O2 |
CAS No. | 875320-29-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 79 mg/mL (200.26 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.535 mL | 12.6752 mL | 25.3505 mL | 63.3762 mL |
5 mM | 0.507 mL | 2.535 mL | 5.0701 mL | 12.6752 mL | |
10 mM | 0.2535 mL | 1.2675 mL | 2.535 mL | 6.3376 mL | |
20 mM | 0.1268 mL | 0.6338 mL | 1.2675 mL | 3.1688 mL | |
50 mM | 0.0507 mL | 0.2535 mL | 0.507 mL | 1.2675 mL | |
100 mM | 0.0254 mL | 0.1268 mL | 0.2535 mL | 0.6338 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Quisinostat 875320-29-9 Apoptosis Autophagy Chromatin/Epigenetic DNA Damage/DNA Repair HDAC deacetylase JNJ 26481585 inhibit hematologic Inhibitor 奎诺司他 Histone deacetylases histone JNJ26481585 JNJ-26481585 malignancies inhibitor